[1] 中华医学会血液学分会血栓与止血学组. 成人原发免疫性血小板减少症诊断与治疗中国指南(2025年版)[J]. 中华血液学杂志,2025,46(12):1105-1113. [2] Liu X G,Hou Y,Hou M.How we treat primary immune throm bocytopenia in adults[J]. J Hematol Oncol,2023, 16(1):4. [3] Vrbensky J R,Moore J E,Arnold D M,et al.The sensitivity and specificity of platelet autoantibody testing in immune thrombocytopenia: a systematic review and meta-analysis of a diagnostic test[J]. J Thromb Haemost, 2019,17(5):787-794. [4] 徐龙伟,曹峰,张耀东,等. 免疫性血小板减少症299例自身抗体表达及预后影响因素分析[J]. 临床儿科杂志,2024, 42(4):318-322. [5] Chen Y W,Hu J D,Chen Y Y.Platelet desialylation and TFH cells-the novel pathway of immune thrombocytopenia[J]. Exp Hematol Oncol,2021,10(1):21. [6] Li J E,van der Wal D E,Zhu G H,et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia[J]. Nat Commun,2015,6:7737. [7] 蒋艺枝. 去唾液酸化血小板在肝脏清除的机制研究[D]. 苏州:苏州大学,2021. [8] 马静瑶,陈振萍,谷昊,等. 去唾液酸化对免疫性血小板减少症影响的研究进展[J]. 中国实验血液学杂志,2018, 26(3):928-932. [9] Audia S,Mahévas M,Samson M,et al.Pathogenesis of immune thrombocytopenia[J]. Autoimmun Rev,2017, 16(6):620-632. [10] Vrbensky J R,Nazy I,Clare R,et al.T cell-mediated autoimmunity in immune thrombocytopenia[J]. Eur J Haematol,2022,108(1):18-27. [11] Sachs U J,Reich M,Qiu D,et al.Platelet autoantibodies have an impact on the platelet count in patients[J]. J Thromb Haemost,2025,23(7):2322-2326. [12] Campbell K,Rishi K,Howkins G,et al.A modified rapid monoclonal antibody-specific immobilization of platelet antigen assay for the detection of human platelet antigen (HPA) antibodies:a multicentre evaluation[J]. Vox Sang, 2007,93(4):289-297. [13] Killie M K,Salma W,Bertelsen E,et al.Quantitative MAIPA: comparison of different MAIPA protocols[J]. Transfus Apher Sci,2010,43(2):149-154. [14] Lochowicz A J,Curtis B R.Clinical applications of platelet antibody and antigen testing[J]. Lab Med,2011, 42(11):687-692. [15] Kashiwagi H,Kuwana M,Murata M,et al.Reference guide for the diagnosis of adult primary immune thrombocytopenia,2023 edition[J]. Int J Hematol,2024, 119(1):1-13. [16] Zhai J P,Ding M Y,Yang T J,et al.Flow cytometric immunobead assay for quantitative detection of platelet autoantibodies in immune thrombocytopenia patients[J]. J Transl Med,2017,15(1):214. [17] 张小侠,曾庆曙,李庆生,等. 流式微球芯片俘获技术对免疫性血小板减少症患者抗体的检测及临床意义[J]. 安徽医科大学学报,2021,56(2):311-315. [18] Porcelijn L,Huiskes E,de Haas M. Progress and development of platelet antibody detection[J]. Transfus Apher Sci,2020,59(1):102705. [19] Martínez-Botía P,Meinders M,De Cuyper I M,et al. Dissecting platelet proteomics to understand the pathophysiology of immune thrombocytopenia: studies in mouse models[J]. Blood Adv,2022,6(11):3529-3534. [20] Cao Q Q,Zhu H Y,Xu W,et al.Predicting the efficacy of glucocorticoids in pediatric primary immune thrombocytopenia using plasma proteomics[J]. Front Immunol,2023,14:1301227. [21] 梅恒,胡豫. 成人原发免疫性血小板减少症诊断与治疗中国指南(2020年版)解读[J]. 临床内科杂志,2021, 38(6):431-432. [22] Neunert C,Terrell D R,Arnold D M,et al.American Society of Hematology 2019 guidelines for immune thrombocytopenia[J]. Blood Adv,2019,3(23):3829-3866. [23] Bussel J B,Knightly K A.Immune thrombocytopenia (ITP) in pregnancy[J]. Br J Haematol,2024,204(4): 1176-1177. [24] 田雪,张慧娟,申永梅,等. 妊娠期间血小板减少症的发病机制、诊断治疗及其对妊娠结局的影响[J]. 中国妇产科临床杂志,2023,24(3):329-331. [25] 魏亚明,桂嵘,王秋实,等. 血小板抗体检测专家共识[J]. 临床输血与检验,2020,22(1):1-5. [26] Zhang Q H,Huang M,Thomas E R,et al.The role of platelet desialylation as a biomarker in primary immune thrombocytopenia: mechanisms and therapeutic perspectives[J]. Front Immunol,2024,15:1409461. [27] Zheng S S,Perdomo J S.Desialylation and apoptosis in immune thrombocytopenia: implications for pathogenesis and treatment[J]. Curr Issues Mol Biol, 2024,46(11):11942-11956. [28] Bigot P,Auffret M,Gautier S,et al.Unexpected platelets elevation in a patient with idiopathic thrombocytopenia treated with oseltamivir for influenza infection[J]. Fundam Clin Pharmacol,2016,30(5):483-485. [29] Revilla N,Corral J,Miñano A,et al.Multirefractory primary immune thrombocytopenia;targeting the decreased sialic acid content[J]. Platelets,2019,30(6): 743-751. [30] Xu M,Liu J C,Huang L L,et al.A novel scoring model for predicting efficacy and guiding individualised treatment in immune thrombocytopaenia[J]. Br J Haematol, 2024,205(3):1108-1120. [31] Cooper N,Bussel J B,Kaźmierczak M,et al.Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised,double-blind, placebo-controlled phase 3 studies and their open-label extension[J]. Br J Haematol,2025,206(2):675-688. [32] Kuter D J,Ghanima W,Cooper N,et al.Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study[J]. Blood,2025,145(24):2914-2926. [33] 梁子杨,张国扬,娜仁朵兰,等. 免疫性血小板减少症治疗新进展[J]. 血栓与止血学,2023,29(2):89-96. [34] Al-Samkari H,Rosovsky R P,Karp Leaf R S,et al. A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia[J]. Blood Adv,2020,4(1):9-18. [35] Al-Samkari H.Platelet autoantibodies have been, and continue to be,clinically relevant in immune thrombocytopenia[J]. J Thromb Haemost,2025,23(7): 2101-2103. [36] 黄雪原, 陈秉宇, 周明,等. 血小板抗体检测的多中心临床应用调查——基于中国10家单位的2 338例病例对照研究[J]. 临床输血与检验,2020,22(2):113-117. |